Pasithea Therapeutics Priced $5M Private Placement of $1.2M Shares At $4.10/Share to Advance Next-Gen Cancer Treatments
Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Express News | Pasithea Therapeutics Announces $5 Million Private Placement Priced at-the-Market Under Nasdaq Rules
Express News | Pasithea Therapeutics Corp - No Treatment-Related Adverse Events or Dose-Limiting Toxicities Observed
Express News | Pasithea Therapeutics Corp - Patient With Stage 3 Colon Cancer Achieves Prolonged Stable Disease
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data From Its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
